Literature DB >> 18574128

Acne vulgaris and acne rosacea as part of immune reconstitution disease in HIV-1 infected patients starting antiretroviral therapy.

Christopher Scott1, Richard C D Staughton, Christopher J Bunker, David Asboe.   

Abstract

Immune reconstitution disease (IRD) has been widely reported following the commencement of antiretrovirals. We report a case series from a cohort of HIV-1-infected patients of whom four developed acne vulgaris and one developed acne rosacea after the initiation of antiretroviral therapy. Acne vulgaris, as part of IRD, has been reported only once in the literature, whereas acne rosacea has not, to our knowledge, previously been described. This serves as a reminder not to overlook dermatological manifestations of disease in patients with HIV infection after starting antiretrovirals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18574128     DOI: 10.1258/ijsa.2008.008026

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  3 in total

1.  Skin Disease in Korean Human Immunodeficiency Virus Patient.

Authors:  Hye Jung Jung; Ji Young Ahn; Dong Hyek Jang; Jae In Lee; Joo Yoon Bae; Mi Youn Park
Journal:  Ann Dermatol       Date:  2019-10-31       Impact factor: 1.444

2.  Case Report: A New Gain-of-Function Mutation of STAT1 Identified in a Patient With Chronic Mucocutaneous Candidiasis and Rosacea-Like Demodicosis: An Emerging Association.

Authors:  Martin Martinot; Anne Sophie Korganow; Mathieu Wald; Julie Second; Elodie Birckel; Antoine Mahé; Laurent Souply; Mahsa Mohseni-Zadeh; Laure Droy; Julien Tarabeux; Satoshi Okada; Mélanie Migaud; Anne Puel; Aurelien Guffroy
Journal:  Front Immunol       Date:  2021-12-20       Impact factor: 7.561

3.  Editorial: Infectious Agent-Induced Chronic Immune Activation: Causes, Phenotypes, and Consequences.

Authors:  Caroline Petitdemange; Nicholas Funderburg; John Zaunders; Pierre Corbeau
Journal:  Front Immunol       Date:  2021-12-10       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.